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Synthesis and Reactivity of Oxazinoindolones via Regioselective 6-
exo-dig Iodolactonization Reaction 
 
Sokaina Hammoud,[a] Elsa Anselmi,[a, b] Khalil Cherry,[c] Jean-Claude Kizirian,[a] and Jérôme Thibonnet*[a] 
 
Abstract: An efficient protocol for facile construction of 3,4-dihydro-10-iodo-3-iodomethylene-[1,4]-
oxazino[4,3-a]indol-1-ones has been developed by using a regio- and stereoselective iodolactonization 
reaction. Subsequent palladium cross-coupling reactions of 3,4-dihydro-10-iodo-3-iodomethylene-
[1,4]-oxazino[4,3-a]indol-1-ones readily afforded functionalized oxazinoindolones. 
 
Introduction 
Substituted N-fused indole moieties are important heterocyclic molecules that are present in a large 
number of naturel products, pharmaceuticals, alkaloids, and agrochemicals and exhibit potent and 
wide-ranging biological activity.[1] In particular, indole-fused oxazinones gained considerable attention 
in recent years because of their great importance in biological sciences and they are also of interest in 
the field of optoelectronic materials.[2] There are various tricyclic oxazinoindolones among which are 
the structures A, B or C (Figure 1). Substituted 3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-ones C have 
attracted much attention due to the broad scope of their biological activities. They are mainly 1,2-
fused system types with six-membered rings fused to indoles with substituents on C3, C8 and C10. For 
example, a recent patent reported the effectiveness of the corresponding oxazinoindolone 1 as an 
anticancer agent.[3] Oxazinoindolones 2 and 3 showed anti-inflammatory[4] and herbicidal activities,[5] 
respectively (Figure 1). Moreover, oxazinoindolones can be used as intermediates in the chemistry of 
bioactive compounds.[6] Also, 1,2-fused oxazinoindolones have rarely been described in the literature 
and much less than the 2,3-fused system. So, we envisioned that the incorporation of the indole moiety 
into the oxazinone scaffold may lead to potentially bioactive molecules. The exploration of new 
methodologies that allow rapid access to these N-fused polycyclic indole scaffolds remains an 
important challenge facing organic chemists.  
Synthetic methods for access to this kind of structure include lactonization from the ester or acid 
indoles,[7] transesterification,[3,8] Friedel-Crafts alkylation,[9] cyclodehydration from the free-NH 
indole,[10] aza-Michael addition,[11] copper catalyzed cyclization,[12] hydroamination[13] of the acid 
system and more recently by gold catalyzed cyclization of the carboxylic acid.[14] In contrast to these, 
the construction of oxazinoindolones by iodolactonization is rare. To the best of our knowledge, there 
is only one report by B. Joseph et al. which described a system with NIS and 2,6-lutidine at -20 °C 
allowing the formation of iodo-oxazinoindolone.[15] Herein, we report a new protocol for the synthesis 
of a variety of substituted 1,2-fused indoles under mild reaction conditions using an iodolactonization 
methodology. 
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Figure 1. Fused tricyclic oxazinoindolone derivatives 
and examples of N-fused polycyclic indole scaffolds. 
 
Driven by our interest in the preparation of 1,2-fused polycyclic indoles, and in conjunction with our 
successful previous research on the tandem coupling/cyclization reaction of iodo-carboxylic indoles,[16] 
we explored the reactivity of carboxylic N-propargylic indoles in the iodolactonization reaction, 
followed by palladium cross-coupling functionalization of the residual iodine. This approach allows the 
preparation of original substituted oxazinoindolones in positions 3 and 10 (Scheme 1). 
 
Scheme 1. Synthesis of indoles fused at 2,3 and 1,2. 
 
Results and Discussion 
The appropriate cyclization precursors were obtained by successive electrophilic iodination, N-
alkylation of the ester indole, followed by saponification of the ester. Two different approaches were 
explored, from the starting iodine propargyl indole acids, or from a non-iodinated precursor (Scheme 
2). 
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We started by the iodination reaction of the ester indole 4 (commercially available or synthesized by 
the Hemetsberger-Knittel method)[17] with the NaI/NCS system.[18] This method allowed the 
preparation of various alkyl 3-iodo-1H-indole-2-carboxylates 5, obtained cleanly and in excellent yields 
after simple recrystallization. 
 
 
Scheme 2. Precursor preparation. 
 
We next turned our attention to the N-propargylation of the resulting iodo-indole compounds. The N-
alkylation reaction was carried out with NaH.[20] Initially, the reaction was performed with 1.1 equiv. 
of NaH followed by 1.2 equiv. of propargylic bromide in THF at room temperature. Only 30% 
conversion was observed. The choice of solvent was then optimized and we found that using DMF, we 
effectively improved the conversion to reach 94% for the product 6a in only 3 hours. It should be noted 
that the use of an excess of NaH and propargyl bromide leads to both N-propargylation and also to 
transesterification of the ethyl ester to the propargyl ester, in accordance with Vandavasi’ work.[21] The 
scope was investigated with the iodine indoles 5 to afford the N-propargylated indoles 6a-6f and 6k 
with good yields. In the same experimental conditions, products 6g-6h were obtained from the 
corresponding tosylate substrates. The preparation of the non-iodinated substrates 6i-6k was also 
carried out for the study of the following iodolactonization reaction. 
 
We also attempted the iodination of compound 6i but only introduction of iodine on the propargyl 
function to give 6’ was observed (38% yield) (Scheme 3). 
 
 
Scheme 3. Iodination of 6i. 
 
Concerning the saponification step, we applied the previously reported conditions to the compound 
6a,[22] which involved 12% aq. KOH in EtOH at 70 °C for 1 h, to produce a mixture of compound 7a and 
its allene isomer 8 (62/38). Screening was pursued with various amounts of KOH and different reaction 
times (Scheme 4). We observed the formation of the allene 8 as the major product (90/10) when the 
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temperature was increased to 70 °C with 23% aq. KOH. The reaction conducted at 45 °C with aq. KOH 
12% led to the N-propargyl acid indole 7a with only 5% of the allene 8. 
 
 
Scheme 4. Optimization of the saponification reaction conditions. 
 
The reaction of the different esters 6 with 3 equivalents of 12% aq. KOH in ethanol at 45 °C afforded 
the corresponding acids 7 with good to excellent yields (Scheme 5). The moderate yield of 7f could be 
explained by its low solubility, leading to difficulties during the purification process. However for 7e 
only the transesterification product was observed. After optimization of the conditions (changing the 
solvent to MeOH, 2 days at 100 °C), 53% yield of 7e was obtained. The saponification was also 
performed on non-iodinated substrates 7i-7k with excellent results.  
 
Yields refer to isolated product. [a] MeOH, 100 °C, 2 days. 
Scheme 5. Scope of the saponification step. 
 
For the iodolactonization reaction, we initially tested the non-iodinated substrate 1-(prop-2-yn-1-yl)-
1H-indole-2-carboxylic acid 7k. Different iodine sources, bases, solvents and temperatures were 
investigated and the results are summarized in Table 1. Interestingly, the reaction provides exclusively 
the six-membered ring product but always with a mixture of mono- 9k and di-iodinated 10a products 
(Table 1, entries 1-6). The use of I2 and NaHCO3[23] gave a better result than NIS and lutidine[24] but we 
5 
 
still obtained a mixture of mono and di-iodinated products (entries 1-3). Temperature had no 
significant effect on the observed results (entry 3). In the presence of iodine, silver nitrate and sodium 
carbonate in THF at room temperature overnight, we obtained the same result, with the di-iodinated 
10a as the major product but mixed with 9% of mono-iodinated 9k (entry 6). Indeed, this system, 
described by Xu Zhang et al.[25] in 2011, is an effective protocol for the synthesis of fused 
benzimidazoles using iodine and silver nitrate through exo- or endo-dig cyclization pathways. Silver 
nitrate is an important additive that significantly improves the reaction yield because it prevents the 
formation of the bis-iodine by-product.[26] We then tried to optimize these conditions by varying the 
quantity of reagents, but unfortunately we always had a small amount (9%) of mono-iodinated product 
and it was impossible to remove it from the mixture. 
 
Table 1. Optimization of the iodolactonization step 
N
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Reagent 
(equiv.) 
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(°C) 
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e 
(h) 
Rati
o 
9k/1
0a 
[%][a] 
1 
NIS (2), 
 2,6-lutidine 
(1,5) 
CH2C
l2 
-20 3.5 
17/8
3 
2 
I2 (2), 
NaHCO3 (2) 
CHCl
3/H2
O 
0 2.5 
12/8
8 
3 
I2 (2), 
NaHCO3 (2) 
CHCl
3/H2
O 
70 4 8/92 
4 
I2 (1), Na2CO3 
(3), AgNO3 
(1)[b] 
THF 20 12 
71/1
4 
5 
I2 (3), Na2CO3 
(3), AgNO3 
(1) 
THF 20 12 
58/4
2 
6 
I2 (8), Na2CO3 
(3), AgNO3 
(1) 
THF 20 12 9/91 
[a] 1H NMR analysis. [b] 15% of starting material. 
 
Finally, we prefered to carry out the reaction on the acid 7a to obtain only the di-iodinated product 
10a in the presence of Na2CO3 (3 equiv.), I2 (1.5 equiv.) and AgNO3 (1 equiv.) in THF at r.t. (Scheme 6). 
6 
 
Under these conditions, a good yield (86%) of isolated pure (E)-oxazinoindol-1-one 10a was obtained 
and the structure of this compound was unambiguously determined by a single-crystal X-ray diffraction 
study (Scheme 6, for details see Supporting Information SI-1).[27] The scope of the reaction was then 
investigated directly with the iodinated precursors 7b-7h (Scheme 6). The products 10a-10e were 
cleanly obtained by a simple recrystallization in moderate to good yields (41-92%). Furthermore, the 
scope of this iodolactonization reaction was examined by using electron-rich or electron-deficient 
substrates which successfully underwent this transformation with high stereoselectivity. Significantly, 
the protocol is also tolerant to R3 substituents (Me or Ph) to furnish the products 10g and 10h in 79% 
and 87% yield respectively. The lower yields for 10b, 10f and 10e could be due to poor solubility of the 
corresponding starting material and of the final desired product, but also formation of the by-product 
from iodine decarboxylation, already described in the literature.[23] After successfully examining the 
substrate scope, we performed a gram-scale synthesis of 10a (3.24 g) starting from 7a. 
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Scheme 6. Scope of the iodolactonization and X-Ray structure of compound 10a  
with displacement ellipsoids drawn at the 50% probability level. 
 
Considering stereoselectivity aspects, (Z)-isomers were never observed in the crude reaction mixtures. 
Addition of iodine to 10a (3 equiv. for 7 days) did not allow us to observe the formation of the (Z)-
isomer. The thermodynamic stabilities of these two diastereoisomers were also evaluated by AM1 
calculations (B3LYP theory) with the B3LYP-def2-TZVP basis set. The results reveal a higher stability of 
the E vs. Z stereoisomer, with a difference of stability close to 1.1 kJ mol-1 (0.26 kcal mol-1).[28, 29] 
A proposed plausible mechanism for the iodolactonization is depicted in Scheme 7 on the basis of the 
literature [26, 30] and our own observations. First, the alkyne function in the carboxylate A is activated 
by coordination to the electrophilic iodine source I+ to furnish the corresponding cyclic iodonium B. 
Subsequently, regioselective intramolecular nucleophilic attack of the oxygen then proceeds via a 6-
exo-trig ring-closing pathway to form the oxazinoindolones 10. Addition of silver nitrate probably allow 
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an ionic reaction.[31] The formation of AgI in the reaction medium will prevent the iodide ions from 
attacking the intermediate B, avoiding the formation of bis-iodinated by-products.  
 
 
Scheme 7. Proposed mechanism for iodolactonization. 
 
We also performed the iodolactonization in these conditions on the allene 8. It resulted in the 
formation of an unseparable mixture of compounds including 10a and other undetermined products. 
Having established a set of conditions for the formation of di-iodide compounds, we turned our 
attention to the functionalization of such derivatives, by exploiting the reactivity of both carbon-iodine 
bonds by employing them in various cross-coupling reactions (Scheme 8). Iododerivatives 10a-k were 
first functionalized through a Stille cross coupling reaction.[32] This reaction has many advantages, 
because the organotin reagents are easily prepared, have a high stability against oxidation and heating, 
and tolerate a wide variety of sensitive functional groups.[33] This popular method has often been used 
in the synthesis of synthetic natural products.[34] 
 
 
Scheme 8. C-C coupling reactions: Stille, Sonogashira or Suzuki. 
 
The reaction was carried out in classical conditions, and the results are summarized in Scheme 9. Stille 
coupling was first performed in the presence of tri-n-butyl(vinyl)stannane (1.1 equiv.), and a catalytic 
amount of PdCl2(MeCN)2 in DMF at room temperature. Under these stoichiometric conditions, mono-
coupling was successfully achieved and regioselectively on the exocyclic vinyl iodine, providing the 
desired tricyclic derivatives 11a, 11c and 11d in 61-83% yield. Significantly, the protocol is also tolerant 
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to R3 substituents (Me or Ph) to afford the products 11f and 11g in 74% and 40% yield respectively. 
The Stille mono-coupling with (E)-trimethyl(2-(tri-n-butylstannyl)vinyl)silane gave products 11b and 
11e in lower yields (38% and 48% respectively). Coupling carried out in the presence of an excess of 
tri-n-butyl(vinyl)stannane (3 equiv.) under the same operating conditions made it possible to react the 
second carbon-iodine bond, but gave the corresponding products with low yields, respectively 30% 
and 26% (12a, 12b). A simple method for the removal of organotin residues was by column 
chromatography using 10% w/w anhydrous K2CO3-SiO2 as the stationary phase.[35]  
 
To explain this difference in reactivity of the two C-I bonds, we performed various calculations and 
analyzed the X-ray structure of 10a.[28] The X-ray analysis shows that the C-I bond [2.059 (6) A˚] of the 
endocyclic-iodine (C7I1) moiety is slightly shorter than the C-I bond [2.076 (6) A˚] of the exocyclic-
iodine (C12-I2) (Scheme 6). By calculation, we can see that C-I distances are smaller in the case of the 
iodine atom localised in the endocyclic position as the C15-I17 distances: 2.095 Å vs that obtained by 
looking at C5-I6 (2.106 Å). Furthermore, the I17C15C16C2 dihedral angle is close to 1.6°, while the 
dihedral angle is close to 183.7° for O3C4C5I6. This shows in fact that the iodine atom in position 17 is 
in the same 3D Euclidean space than atoms in composing the aromatic cycles, which is not the case of 
iodine in the position exocyclic (see Supporting Information SI-2). These differences in bond distances 
and dihedral angles could explain the better reactivity of this exocyclic-iodine when the Pd catalyst is 
used. 
 
Scheme 9. Structures and yields of the Stille coupling. Reagents and 
conditions: vinyltin (1.1 equiv.), PdCl2MeCN2 (5 mol%), DMF, r.t., 18 h. 
 
For Sonogashira[36] coupling we first investigated the reactivity of the exocyclic carbon-iodine bond 
(Scheme 10). The first tests were attempted on compounds 10a-10c and 1-hexyne using palladium 
acetate, copper iodide as catalyst, triethyamine and DMF as solvent at room temperature. The 
corresponding 11h-11j were obtained with a moderate to good yields (48-85%). However, the use of 
the alkynes phenylacetylene or methoxypropyne with 10a allowed us to obtain the products 11i and 
11j only with low yields (27% and 11% respectively), resulting probably from the duplication of terminal 
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alkynes. A double Sonogashira coupling reaction with hexyne and di-iodide 10a furnished 12c but only 
in 34% yield. 
 
Scheme 10. Structures and yields of the Sonogashira and Suzuki couplings. 
[a] Reagents and conditions for Sonogashira: Alkyne (1.5 equiv.), CuI (10 mol%), PPh3 (10 mol%), 
Pd(OAc)2 (5 mol%), Et3N, DMF, 15 h. [b] Reagents and conditions for Suzuki coupling: R3BF3K (1.2 equiv.), 
PdCl2dppf (5 mol%), Cs2CO3 (1.5 equiv.), toluene/H2O (5/1), 70 °C, 24 h. 
 
Starting from compound 10a we finally tested the reactivity of the exocyclic iodine toward a Suzuki-
Miyaura[37] coupling reaction with 4-methylphenylboronic acid. However a complex and inseparable 
mixture of products was obtained. Finally, we considered the Suzuki–Miyaura cross coupling 
conditions with potassium vinyltrifluoroborate, which is commercially available and air-stable. This 
compound has been widely employed as a versatile vinylating agent in Suzuki–Miyaura cross-coupling 
reactions in recent years, and has proven to be a powerful C2 building block to access a variety of 
styrenic derivatives.[38] 
 
Thus, the use of potassium vinyltrifluoroborate (1.2 equiv.) with compound 10a in the presence of 
cesium carbonate (1.5 equiv.), PdCl2dppf (5 mol%) in a 5:1 mixture of toluene/H2O at 70 °C for 24 h 
furnished 11a in 60 % yield. In addition, potassium vinyltrifluoroborate (3 equiv.) was also an efficient 
coupling partner with 10b for a double transformation to give the desired product 12b in 91% yield. 
Finally, the introduction of a heterocyclic unit as a coupling partner (benzofuran, thiophene, isoxazole) 
allows access to products 11m, 11n and 11o with average to low yields (Scheme 10). 
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We recently developed an efficient method for the Sonogashira decarboxylative cross coupling 
reaction[39] between aryl halides and alkynyl carboxylic acids, and we explored this reaction with 
compound 10d and pent-2-ynoic acid (Scheme 11). The corresponding decarboxylative coupling 
product 13 on the vinyl iodine atom only was isolated in 70% yield. 
 
 
Scheme 11. Sonogashira decarboxylative cross-coupling reaction with 10d. 
 
Finally, we tried to extend this methodology to indoles with longer alkynyl chains in order to obtain 
extended 7-membered or 8-membered cycles (Scheme 12). Compound 14b was synthesized according 
to the previously described procedure with a good yield. However, the same strategy employed for 
the preparation of 14a failed whatever the starting materiel employed (4-bromobut-1-yne, but-3-yn-
1-yl-methylbenzenesulfonate or 4-(trimethylsilyl)but-3-yn-1-yl methylbenzenesulfonate in basic 
conditions). Fortunately, Mitsunobu conditions[40] allowed the formation of the homopropargyl indole 
14a though the yield is low (35%), enabling the next step, saponification, with a good yield (91%). 
Finally, iodocyclization of these two compounds was performed in the conditions described previously, 
and led to the formation of exclusively the exo-dig products in both cases. The low yield could be 
explained by the formation of the corresponding iodinated-decarboxylated by-products (observed in 
the propargyl series). The structures of 16a and 17b, were confirmed by X-ray crystallography (see 
Supporting Information SI-1). Effect of substituant on the alkynyl chain led to the formation of a 
mixture of undetermined products while it is not the case with propargyl chain.[41] 
Despite their ubiquitous existence within various biologically active natural products and 
pharmaceuticals, the formation of 1,2-fused indoles with medium sized rings is generally difficult to 
achieve.[42] The methods for obtaining these products remains a major challenge in organic synthesis 
and they are mainly based on the use of metal complexes.[43] This new methodology therefore makes 
it possible to access new 1,2-fused substituted indoles with medium-sized (seven- to eight-membered) 
carbocyle. 
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Scheme 12. Extended alkynyl chain indoles and  
X-Ray structures of compounds 16a and 17b with displacement ellipsoids. 
 
Finally, we tested iodocyclization in the pyrrole series. By the same methodology previously described 
for commercial pyrrole 18 (N-propargylation with propargyl bromide; saponification with KOH), we 
obtained the pyrrole acid 20 in good yield (Scheme 13).[14, 44] Under the previously used iodocyclization 
conditions [Na2CO3 (3 equiv.), I2 (1.5 equiv.) and AgNO3 (1 equiv.) in THF at r.t.], a moderate yield (30%) 
of isolated pure (E)-pyrrolo-oxazin-1-one 21 was obtained (Scheme 13). The (E)-pyrrolo-oxazin-1-one 
scaffold exhibits wide-ranging biological activity against a multitude targets, making it an important 
intermediate. 
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Scheme 13. Pyrrole extension. 
 
Conclusions 
In summary, we have developed an iodocyclization of N-propargyl indoles, followed by palladium-
catalyzed coupling, providing potential biologically and pharmaceutically important oxazinoindolones 
in moderate to excellent yields. We also carried out analogous transformations to extend this 
methodology with longer alkynyl chain in order to obtain extended 7-membered or 8-membered 
cycles. This method provides straightforward access to 1,2-fused tricyclic indoles. After preliminary 
good results toward resistant bacteria, others tests are in process. 
 
Experimental Section 
General Methods: All reactions were carried out under argon atmosphere in dried glassware. THF was 
distilled under argon from sodium using benzophenone as indicator. Dimethylformamide was dried 
and freshly distilled from calcium hydride. Chemicals were purchased from commercial sources 
(Sigma–Aldrich, Alfa Aesar, Fluorochem or ABCR) and used without further purification except 5b, 5e, 
5f obtained by Hemetsberger-Knittel [1] method and 2c by Fischer [2] method. 
Reactions were monitored by TLC with Merck® Silica gel 60 F254. The developed TLC plates were 
visualized by using UV light (254 nm) or KMnO4. Column chromatography was performed on silica gel 
(40-63 µm) using various mixtures of EtOAc and petroleum ether (35-60 °C fraction) as eluent. 1H NMR 
spectra were recorded on a Bruker® Avance 300 (300 MHz) NMR spectrometer, using as internal 
deuterium lock the solvents CDCl3 (δ 7.26), (CD3)2CO (δ 2.05) or (CD3)2SO (δ 2.54). Chemical shifts are 
quoted in ppm (δH, δC). Peak multiplicities are defined as: s = singlet, d = doublet, t = triplet, q = quartet, 
quin = quintet, sxt = sextet, m = multiplet and br = broad. Coupling constants (J) are reported in Hz. 13C 
NMR was recorded at 75 MHz on the same instrument, using the solvent peak at as reference CDCl3 (δ 
77.16), (CD3)2CO (δ 29.85) or (CD3)2SO (δ 39.52). 19F NMR was recorded at 282 MHz on the same 
instrument, using the CFCl3 as internal reference (δ 0.0). Mass spectra were obtained on a Hewlett 
Packard (engine 5988A) by direct inlet at 70eV. HRMS was obtained with a LCMS-IT-TOF mass 
spectrometer under conditions of ESI. Infrared spectra were recorded on a Perkin-Elmer Spectrum One 
spectrophotometer with the sample being prepared as a thin film on a diamond ATR module. 
Absorption maxima (max) are quoted in wavenumbers (cm-1). Melting points were uncorrected. 
Analytical data for already describes molecules can be find in SI.  
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General procedure for iodination of indoles 
In a two-necked round bottom flask, 4.16 g of NCS (1.2 equiv., 31 mmol) were first dissolved in 40 mL 
of DMF and then, 4.67 g of NaI (1.2 equiv., 31 mmol) was added in small portions and the mixture was 
stirred for 30 min at room temperature. 1 equiv. of indole (26 mmol) was dissolved in 10 mL of DMF 
and added drop by drop to the mixture using a bromine bulb at 0 °C.  
According to the solubility, 2 different protocols: 
Method A: The mixture was stirred for 4 h at room temperature. The medium was hydrolyzed by 10 
mL of Na2S2O3 (20 % aq sol.) and 10 mL of water and then stirred for 30 min. The precipitate formed 
was dissolved with Et2O. The organic phase was washed with NH4Cl (3 × 10 mL), NaCl (2 × 10 mL), dried 
by MgSO4 and evaporated under vacuum before recrystallization with CH2Cl2. 
Method B: The mixture was stirred for 4 h at room temperature. The medium was hydrolyzed by 20 
mL of Na2S2O3 (20 % aq. sol.) and 20 mL of water and then stirred for 30 min. The precipitate was 
filtered on a Büchner funnel and washed by hexane and the precipitate was left to dry for 2 h. 
The following products are already described and in accordance with the litterature : Ethyl 3-iodo-1H-
indole-2-carboxylate (method A) 5a[16]; Methyl 7-iodo-5H-[1,3]dioxolo[4,5-f]indole-6-carboxylate 
(method B) 5b[18b]; Ethyl 5-fluoro-3-iodo-1H-indole-2-carboxylate 5d[18b] (method B). 
 
Ethyl 3-iodo-5-methoxy-1H-indole-2-carboxylate 5c: Method (B). Brown solid (8.7 g, 97 %); m.p. 162-
164 °C; Rf = 0.79 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 9.18 (s, 1 H), 7.28 (d, J = 9 Hz, 1 H), 
7.03 (dd, J = 9 Hz, J = 2.4 Hz, 1 H), 6.92 (d, J = 2.4 Hz, 1 H), 4.45 (q, J = 8 Hz, 2 H), 3.90 (s, 3 H), 1.46 (t, J 
= 7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 160.9, 155.7, 133.0, 131.4, 127.5, 118.7, 113.2, 103.3, 
65.4, 61.6, 55.8, 14.5 ppm. IR (ATR): νmax = 3292, 2976, 1678, 1505, 1248, 1202, 1158, 1019, 771, 671 
cm-1. MS (EI) m/z = 299 (M+., 100), 75 (18), 76 (15), 101 (13), 102 (13), 119 (33), 130 (10), 144 (26), 146 
(14), 284 (23), 300 (15), 345 (56). HRMS (ESI): calcd. for C12H13INO3 [M+H]+ 345.9940; found 345.9936. 
 
Methyl 3-iodo-7-methoxy-1H-benzo[g]indole-2-carboxylate 5e: Method (B). White solid (9.36 g, 91 
%); m.p. 263-265 °C; Rf = 0.41 (EtOAc/PE, 20:80). 1H NMR (300 MHz, DMSO-d6): δ = 8.72 (d, J = 9 Hz, 1 
H), 7.54 (d, J = 9 Hz, 1 H), 7.43 (s, 1 H), 7.42 (d, J = 12 Hz, 1 H), 7.25 (dd, J = 9 z, J = 2.5 Hz, 1 H), 3.93 (s, 
3 H), 3.89 (s, 3 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 160.7, 157.5, 133.7, 133.4, 125.9, 124.9, 123.9, 
122.2, 121.6, 117.2, 116.5, 108.6, 68.6, 55.3, 51.7 ppm. IR (ATR): νmax = 3299, 1685, 1435, 1168, 824, 
663 cm-1. MS (EI) m/z = 382 (16), 381 (M+., 97), 350 (16), 349 (84), 224 (10), 196 (10), 195 (16), 194 
(100), 174 (10), 169 (33), 152 (22), 127 (11), 126 (25), 125 (25), 99 (11), 97 (11), 76 (12), 75 (15), 63 
(11), 51 (52). HRMS (ESI): calcd. for C15H13INO3 [M+H]+ 381.9940; found 381.9930. 
 
Methyl 4-bromo-3-iodo-1H-pyrrolo[3,2-c]pyridine-2-carboxylate 5f: Method (B). White solid (9.73 g, 
95 %); m.p. 229-231 °C; Rf = 0.34 (EtOAc/PE, 50:50). 1H NMR (300 MHz, acetone-d6): δ = 13.08 (s, 1H), 
8.07 (d, J = 5.7 Hz, 1 H), 7.53 (d, J = 5.7 Hz, 1 H), 3.92 (s, 3 H). 13C NMR (75 MHz, DMSO-d6) : δ = 160.2, 
142.1, 141.2, 135.7, 129.7, 123.6, 108.7,  63.9, 52.2. IR (ATR): νmax = 2955, 1713, 1654, 1250, 1184, 940 
cm-1. HRMS (ESI): calcd. for C9H7BrIN2O2 [M+H]+ 380.87301; found 380.87241; calcd. for C9H5BrIN2O2 
[M-H]+ 378.85846, found 378.85915. 
 
Ethyl 1-(3-iodoprop-2-yn-1-yl)-1H-indole-2-carboxylate 6‘: Method (A). solid ( 2.2 g, 38 %). Purification 
by  column chromatography  (eluent EtOAc/PE, 5:95). 1H NMR (300 MHz, CDCl3) δ = 7.69 (d, J = 8.0 Hz, 
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1H), 7.49 (d, J = 8.2 Hz, 1H), 7.44 - 7.33 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 5.58 (s, 2H), 4.40 (q, J = 7.1 Hz, 
2H), 1.42 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 162.0, 139.0, 127.0, 126.2, 125.6, 122.8, 121.2, 
111.5, 110.6, 89.2, 72.1, 60.9, 35.7, 14.4. HRMS (ESI): calcd. for C14H13INO2 [M+H]+ 353.9991; found. 
353.9976. 
 
General procedure for N-alkylation: In a two-necked round bottom flask, 0.82 g of NaH 60 % (1.3 
equiv., 20.6 mmol) were dissolved in 15 mL of DMF, and 1 equiv. of compound 5 (15.8 mmol) in 10 mL 
of DMF were added drop by drop using a syringe at 0 °C under argon. The mixture was stirred for 30 
min at room temperature. 1.3 equiv. of propargyl bromide 80 % (20.6 mmol) or tosylate were diluted 
with DMF and added to the mixture drop by drop using a syringe at 0 °C under argon. After 4 h of 
stirring at room temperature, the mixture was hydrolyzed by 10 mL of NH4Cl, extracted by diethyl ether 
(7 × 20 mL), and the organic phase was washed with NaCl (6 × 10 mL), dried by MgSO4 and evaporated 
under vacuum. The product is obtained pure or the residue was purified by column chromatography 
(eluent EtOAc/hexane).  
 
The following products are already described and in accordance with the litterature : Ethyl 1-(prop-2-
ynyl)-1H-indole-2-carboxylate 6i[14]; 1-(but-2-ynyl)-1H-indole-2-carboxylic acid 6k. [14] 
 
Ethyl 3-iodo-1-(prop-2-yn-1-yl)-1H-indole-2-carboxylate 6a: Yellow solid (5.3 g, 95 %); m.p. 84-86 °C; 
Rf = 0.67 (EtOAc/hexane, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.59 (d, J = 9 Hz, 1 H), 7.46-7.44 (m, 2 
H), 7.30-7.25 (m, 1 H), 5.40 (d, J = 3 Hz, 2 H), 4.49 (q, J = 8 Hz, 2 H), 2.27 (t, J = 2.5 Hz, 1 H), 1.51 (t, 3H, 
J = 6 Hz) ppm. 13C NMR (75 MHz, CDCl3): δ = 161.2, 138.3, 130.7, 127.6, 126.7, 124.3, 122.0, 110.7, 
78.6, 72.5, 69.0, 61.6, 35.2, 14.3 ppm. IR (ATR): νmax = 3277, 2985, 2121, 1690, 1609, 1568 cm-1. HRMS 
(ESI): calcd. for C14H13O2NI [M+H]+ 353.9991; found 353.9904. 
 
Methyl 7-iodo-5-(prop-2-yn-1-yl)-5H-[1,3]dioxolo[4,5-f]indole-6-carboxylate 6b: White solid (6.09 g, 
97%); m.p. 180-182 ° C; Rf = 0.49 (EtOAc/hexane, 20:80). 1H NMR (300 MHz, CDCl3): δ = 6.94 (s, 1 H), 
6.87 (s, 1 H), 6.02 (s, 2 H), 5.34 (d, J = 3 Hz, 2 H), 3.96 (s, 3 H), 2.28 (t, J = 2.5 Hz, 1 H) ppm.13C NMR (75 
MHz, CDCl3): δ = 161.4, 149.3, 145.5, 134.6, 126.2, 125.5, 101.9, 101.7, 90.7, 78.4, 72.7, 69.1, 51.7, 35.5 
ppm. IR (ATR): νmax = 3260, 3001, 2952, 2895, 2123, 1690, 1509, 1495, 1480 cm-1. HRMS (ESI): calcd. 
for C14H11INO4 [M+H]+ 383.9727; found 383.9719. 
 
Ethyl 3-iodo-5-methoxy-1-(prop-2-yn-1-yl)-1H-indole-2-carboxylate 6c: Brown solid (5.75 g, 95 %); 
m.p. 108-110 °C; Rf = 0.62 (EtOAc/PE, 20:80). 1H NMR (300 MHz, acetone-d6): δ = 7.57 (d, J = 9 Hz, 1 H), 
7.12 (dd, J = 9 Hz, 3 Hz, 1 H), 6.95 (d, J = 3 Hz, 1 H), 5.47 (d, J = 3 Hz, 2 H), 4.45 (q, J = 7 Hz, 2 H), 3.89 (s, 
3H), 2.80 (t, J = 2.5 Hz, 1 H), 1.47 (t, J = 7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, acetone-d6): δ = 161.4, 
156.9, 134.3, 131.8, 128.9, 118.7, 113.2, 104.3, 79.8, 73.8, 67.7, 61.9, 55.9, 35.7, 14.5 ppm. IR (ATR): 
νmax = 3277, 2923, 1689, 1500, 1257, 1021, 772, 681 cm-1. HRMS (ESI): calcd. for C15H15INO3 [M+H] 
384.0091; found 384.0092. 
 
Ethyl 5-fluoro-3-iodo-1-(prop-2-yn-1-yl)-1H-indole-2-carboxylate 6d: White solid (5.51 g, 94 %); m.p. 
249-251 °C; Rf = 0.66 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.42 (dd, J = 3 Hz, 9 Hz, 1 H), 
7.29-7.16 (m, 3 H), 5.39 (d, J = 3 Hz, 2 H), 4.49 (q, J = 7 Hz, 2 H), 2.28 (t, J = 2.2 Hz, 1 H), 1.51 (t, J = 7.5 
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Hz, 3 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 160.2, 158.4 (d, JC-F = 238 Hz), 134.7, 130.4 (d, JC-F = 9 
Hz), 129.4, 115.3 (d, JC-F = 26 Hz), 113.6 (d, JC-F = 9 Hz), 107.6 (d, JC-F = 25 Hz), 79.2, 75.1, 68.7, 61.5, 35.3, 
14.05 ppm. 19F NMR (252 MHz, CDCl3): δ = -121.37 (td, J = 9 Hz, J = 4 Hz). IR (ATR): νmax = 3284, 2983, 
1686, 1497, 1380, 1263, 1161 cm-1. HRMS (ESI): calcd. for C14H12FINO2 [M+H]+ 371.9891; found 
371.9892. 
 
Methyl 3-iodo-7-methoxy-1-(prop-2-yn-1-yl)-1H-benzo[g]indole-2-carboxylate 6e: White solid (5.06 
g, 74 %); m.p: 197-199 °C; Rf = 0.52 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 8.60 (d, J = 12 Hz, 
1 H), 7.60-7.51 (m, 2 H), 7.34-7.28 (m, 2 H), 5.69 (d, J = 3 Hz, 2 H), 4.02 (s, 3H), 3.97 (s, 3H), 2.47 (t, J = 
2.4 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 161.7, 157.6, 135.9, 134.6, 126.9, 126.8, 124.1, 123.6, 
123.1, 117.4, 116.9, 109.4, 79.2, 73.9, 71.5, 55.5, 51.8, 39.1. IR (ATR): νmax = 3278, 1697, 1467, 1258, 
1174, 690 cm-1. HRMS (ESI): calcd. for C18H15INO3 [M+H]+ 420.0091; found 420.0092. 
 
Methyl 4-bromo-3-iodo-1-(prop-2-yn-1-yl)-1H-pyrrolo[3,2-c]pyridine-2-carboxylate 6f: Beige solid 
(5.54 g, 81 %); m.p. 162-164 °C; Rf = 0.28 (EtOAc/PE, 50:50). 1H NMR (300 MHz, CDCl3): δ = 8.21 (d, J = 
5.9 Hz, 1 H), 7.42 (d, J = 5.9 Hz, 1 H), 5.28 (d, J = 2.5 Hz, 2 H), 4.04 (s, 3 H), 2.35 (t, J = 2.5 Hz, 1 H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 161.3, 143.1, 137.9, 123.7, 106.2, 105.7, 76.9, 73.9, 73.8, 65.3, 52.6, 35.9 
ppm. IR (ATR): νmax = 3275, 2129, 1707, 1440, 1179, 1120 cm-1. HRMS (ESI): calcd. for C12H9BrIN2O2 
[M+H]+ 419.8920; found 419.8911. 
 
Ethyl 1-(but-2-yn-1-yl)-3-iodo-1H-indole-2-carboxylate 6g:. White solid (3.30 g, 57 %); m.p. 96-98 °C; 
Rf = 0.7 (EtOAc/PE, 20:80).1H NMR (300 MHz, CDCl3): δ = 7.58 (dt, J = 8 Hz, J = 1 Hz, 1 H), 7.48-7.40 (m, 
2 H), 7.29-7.23 (m, 1 H), 5.33 (q, J = 3 Hz, 2 H), 4.49 (q, J = 7 Hz, 2 H), 1.74 (t, J = 2.3 Hz, 3 H), 1.51 (t, J = 
6 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 161.2, 138.3, 130.6, 127.7, 126.4, 124.1, 121.9, 110.9, 
80.3, 74.0, 68.2, 61.5, 35.6, 14.3, 3.6 ppm. IR (ATR): νmax = 2976, 1691, 1452, 1260, 1192, 739. HRMS 
(ESI): calcd. for C15H15INO2 [M+H]+ 368.0142; found 368.0141. 
 
Ethyl 3-iodo-1-(3-phenylprop-2-yn-1-yl)-1H-indole-2-carboxylate 6h: Yellow oil (5.02 g, 74 %); Rf = 0.7 
(EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.61 (d, J = 6 Hz, 1 H), 7.54 (d, J = 6 Hz,1 H), 7.46 (t, J 
= 7.5 Hz, 1 H), 7.37-7.23 (m, 6 H), 5.62 (s, 2 H), 4.51 (q, J = 8 Hz, 2 H), 1.52 (t, J = 7.5 Hz, 3 H) ppm. 13C 
NMR (75 MHz, CDCl3): δ = 161.2, 138.4, 131.8, 130.6, 128.5, 128.3, 127.7, 126.6, 124.2, 122.4, 122.0, 
110.9, 84.2, 84.0, 68.6, 61.6, 36.0, 14.3 ppm. IR (ATR): νmax = 2981, 1698, 1240, 1191, 741, 690. HRMS 
(ESI): calcd. for C20H17INO2 [M+H]+ 430.0298; found 430.0299. 
 
Ethyl 1-(3-phenylprop-2-yn-1-yl)-1H-indole-2-carboxylate 6j: Yellow oil (4.65 g, 97 %); Rf = 0.86 
(EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.70 (d, J = 9 Hz, 1 H), 7.61 (d, J = 9 Hz, 1 H), 7.41-7.18 
(m, 8 H), 5.68 (s, 2 H), 4.41 (q, J = 7 Hz, 2 H), 1.43 (t, J = 7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 
162.2, 139.2, 131.9, 128.4, 128.3, 127.2, 126.3, 125.4, 122.8, 122.7, 121.1, 111.4, 111.0, 84.3, 83.8, 
60.9, 34.8, 14.5 ppm. IR (ATR): νmax = 2981, 1702, 1455, 1192, 748. HRMS (ESI): calcd. for C20H18NO2 
[M+H]+ 304.1332; found 304.1330. 
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General procedure for saponification  
In a round bottom flask, indole ester 6 (1 equiv., 7.5 mmol) was dissolved in 20 mL of ethanol before 
the addition of 10.5 g of 12% aq. KOH (3 equiv., 22.5 mmol) slowly. The mixture was stirred and heated 
at 45 °C. After 3 h, the mixture was cooled on an ice bath and acidified with 25 mL of HCl (1 M) to 
obtain pH = 1. The precipitate obtained was filtered on a Büchner funnel and washed with hexane. 
 
Only the 1-(but-2-ynyl)-1H-indole-2-carboxylic acid 7i was already described and is in accordance with 
the literature.[14, 44] 
 
3-Iodo-1-(prop-2-yn-1-yl)-1H-indole-2-carboxylic acid 7a: Beige solid (2.38 g, 98 %); m.p. 196-198 °C; 
Rf = 0.08 (EtOAc/hexane, 20:80). 1H NMR (300 MHz, acetone-d6): δ = 7.67 (d, J = 8.5 Hz, 1 H), 7.56 (d, J 
= 8 Hz, 1 H), 7.49 (t, J = 7.5 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1 H), 5.57 (d, J = 3 Hz, 2 H), 2.82 (t, J = 3 Hz, 1 H) 
ppm.13C NMR (75 MHz, DMSO-d6): δ = 162.0, 137.9, 129.9, 128.8, 126.1, 123.1, 121.8, 111.5, 79.6, 74.7, 
68.9, 34.7 ppm. IR (ATR): νmax = 3277, 3052, 2985, 2121, 1690, 1610, 1568 cm-1. HRMS (ESI): calcd. for 
C12H9O2NI [M+H]+ 325.9678; found 325.9598. 
 
7-Iodo-5-(prop-2-yn-1-yl)-5H-[1,3]dioxolo[4,5-f]indole-6-carboxylic acid 7b: White solid (2.49 g, 90 
%); m.p. 226-228 °C; Rf = 0.08 (EtOAc/ hexane, 20:80). 1H NMR (300 MHz, acetone-d6): δ = 7.16 (s, 1 
H), 6.89 (s, 1 H), 6.19 (s, 1 H), 5.51 (d, J = 3 Hz, 2 H), 2.81 (t, J = 3 Hz, 1 H) ppm. 13C NMR (75 MHz, DMSO-
d6): δ = 161.7, 148.4, 144.8, 134.0, 127.0, 124.5, 101.5, 100.5, 91.6, 79.6, 74.7, 69.3, 35.0 ppm. IR (ATR): 
νmax = 3279, 3261, 2894, 2579, 2506, 2123, 1667, 1509, 1495, 1480 cm-1. HRMS (ESI): calcd. for 
C13H7INO4 [M-H]+ 367.9425; found 367.9424. 
 
3-Iodo-5-methoxy-1-(prop-2-yn-1-yl)-1H-indole-2-carboxylic acid 7c: Beige solid (2.39 g, 90 %); m.p. 
214-216 °C; Rf = 0.21 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.39 (d, J = 9 Hz, 1 H), 7.14 (dd, 
J = 2.5 Hz, J = 9 Hz, 1 H), 7.14 (dd, J 3, 9 Hz, 1 H), 6.96 (d, J = 3 Hz, 1 H), 5.42 (d, J = 3 Hz, 2H), 3.91 (s, 3 
H), 2.28 (t, J = 3 Hz, 1 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 161.9, 155.3, 133.1, 130.3, 128.9, 117.3, 
112.8, 103.1, 79.6, 74.7, 68.1, 55.4, 34.8 ppm. IR (ATR): νmax = 3258, 2922, 2512, 1663, 1500, 1263, 
1170, 1024, 845. HRMS (ESI): calcd. for C13H11INO3 [M+H]+ 355.9778; found 355.9777. 
 
5-Fluoro-3-iodo-1-(prop-2-yn-1-yl)-1H-indole-2-carboxylic acid 7d: White solid (2.21 g, 86 %); m.p. 
229-231 °C; Rf = 0.06 (EtOAc/PE, 20:80). 1H NMR (300 MHz, DMSO-d6): δ = 7.76-7.71 (m, 1 H), 7.32 (t, J 
= 9 Hz, 1 H), 7.19 (d, J = 8.5 Hz, 1 H), 5.46 (bs, 2 H), 3.30 (bs, 1 H) ppm. 13C NMR (75 MHz, DMSO-d6) : δ 
= 161.7, 158.3 (d, JC-F = 237 Hz), 134.6, 130.5, 130.3, 115.0 (d, JC-F = 25 Hz), 113.4 (d, JC-F = 12 Hz), 107.3 
(d, JC-F = 25 Hz), 79.4, 74.9, 67.9 (d, JC-F = 5 Hz), 35.0 ppm. IR (ATR): νmax = 3282, 2836, 1666, 1500, 1257, 
1164, 799. HRMS (ESI): calcd. for C12H6FINO2 [M-H]+ 341.9432; found 341.9438. 
 
3-Iodo-7-methoxy-1-(prop-2-yn-1yl)-1H-benzo[g]indole-2-carboxylic acid 7e: Beige solid (1.61 g, 53 
%); m.p. 217-219 °C; Rf = 0.01 (EtOAc/PE: 20/80). 1H NMR (300 MHz, DMSO-d6): δ = 8.59 (d, J = 9.3 Hz, 
1 H), 7.64 (d, J = 8.8 Hz, 2 H), 7.54-7.49 (m, 2 H), 7.33 (dd, J = 9.2 Hz, J = 2.5 Hz, Hz, 1 H), 5.78 (bs, 2 H), 
3.91 (s, 3 H), 3.44 (bs, 1 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 162.1, 157.0, 135.2, 133.3, 127.9, 
125.9, 124.1, 123.3, 122.4, 117.1, 116.4, 109.4, 79.8, 76.2, 71.4, 55.3, 38.2 ppm. HRMS (ESI): calcd. for 
C17H11INO3 [M-H]+ 403.9783; found 403.9797. 
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4-Bromo-3-iodo-1-(prop-2-yn-1-yl)-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid 7f: White solid (1.76 
g, 58 %); m.p. 233-235 °C; Rf = 0 (EtOAc/PE, 50:50). 1H NMR (300 MHz, DMSO-d6): δ = 8.17 (d, J = 6.0 
Hz, 1 H), 7.86 (d, J = 6.0 Hz, 1 H), 5.38 (d, J = 2 Hz, 2 H), 3.41 (t, J = 2 Hz, 1 H) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 162.3, 142.9, 142.4, 136.2, 123.0, 107.8, 107.6, 78.9, 76.3, 64.7, 35.9 ppm. IR (ATR): νmax 
= 3239, 2900-2412, 1206, 1126, 1070, 804 cm-1. HRMS (ESI): calcd. for C11H7BrIN2O2 [M+H]+ 405.8763; 
found 405.8755. 
 
1-(But-2-yn-1-yl)-3-iodo-1H-indole-2-carboxylic acid 7g: White solid (2.51 g, 99 %);. m.p. 218-220 °C; 
Rf = 0.17 (EtOAc/PE, 20:80). 1H NMR (300 MHz, acetone-d6): δ = 7.63 (d, J = 8.4 Hz, 1 H), 7.55 (dm, J = 
8.1 Hz, 1 H), 7.46 (t, J = 7.2 Hz, 1 H), 7.28 (t, J = 8 Hz, 1 H), 5.47 (q, J = 2.4 Hz, 2 H), 1.69 (t, J = 2.4 Hz, 3 
H) ppm.13C NMR (75 MHz, acetone-d6): δ = 162.4, 139.2, 131.3, 129.4, 127.0, 124.2, 122.6, 112.2, 80.3, 
75.2, 68.1, 35.8, 3.1 ppm. IR (ATR): νmax = 2507, 1665, 1266, 738 cm-1. HRMS (ESI): calcd. for C13H9INO2 
[M-H]+ 337.9683; found 337.9689. 
 
3-Iodo-1-(3-phenylprop-2-yn-1-yl)-1H-indole-2-carboxylic acid 7h: Yellow solid (2.91 g, 97 %); m.p. 
211-213 °C; Rf = 0.18 (EtOAc/PE, 20:80). 1H NMR (300 MHz, acetone-d6): δ = 7.74 (d, J = 8.3 Hz, 1 H), 
7.56 (d, J = 8.1 Hz, 1 H), 7.50 (t, J = 7.2 Hz, 1 H), 7.37-7.28 (m, 6 H), 5.79 (s, 2 H) ppm. 13C NMR (75 MHz, 
acetone-d6): δ = 162.4, 139.3, 132.3, 131.4, 129.4, 129.3, 127.2, 124.4, 123.2, 122.8, 112.2, 85.5, 84.2, 
68.5, 36.3 ppm. IR (ATR): νmax = 2589, 1663, 1434, 742, 688. HRMS (ESI): calcd. for C18H11INO2 [M-H]+ 
399.9839; found 399.9844. 
 
1-(3-Phenylprop-2-yn-1-yl)-1H-indole-2-carboxylic acid 7j: Pale pink solid (1.81 g, 88 %); m.p. 186-188 
°C; Rf = 0.28 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.74 (d, J = 8.5 Hz, 1 H), 7.62 (d, J = 8.5 
Hz, 1 H), 7.53 (d, J = 1 Hz, 1 H), 7.45 (t, J = 8 Hz, 1 H), 7.38-7.35 (m, 2 H), 7.28-7.20 (m, 4 H), 5.69 (s, 2 
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 165.3, 139.8, 132.0, 128.5, 128.3, 126.3, 126.2, 125.6, 123.2, 
121.4, 113.6, 111.1, 84.1, 34.9 ppm. IR (ATR): νmax =  687, 740, 1264, 1444, 1654, 2929. HRMS (ESI): 
calcd. for C18H12NO2 [M-H]+ 274.0873; found 274.0878. 
 
3-Iodo-1-(propa-1,2-dienyl)-1H-indole-2-carboxylic acid 8: 
In a round bottom flask, indole ester 6a (1 equiv., 8.5 mmol) was dissolved in 3 mL of ethanol before 
the addition of 143 mg of KOH 23% (3 equiv., 2.5 mmol) slowly. The mixture was stirred and heated at 
70 °C. After 3 h, the mixture was cooled in an ice bath and acidified with 5 mL of HCl (1 M) to obtain 
pH = 1. The precipitate obtained was filtered on Büchner and washed with hexane. White solid (240 
mg, 87%); m.p. 158 °C. 1H NMR (300 MHz, CDCl3): δ = 7.83-7.73 (m, 2 H), 7.50 (d, J = 8.0 Hz, 1 H), 7.42 
(t, J = 7.7 Hz, 1 H), 7.29 (t, J = 7.4 Hz, 1 H), 5.73 (d, J = 6.5 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 
203.7, 161.9, 137.1, 130.3, 129.4126.3, 123.3, 122.3, 112.4, 96.8, 86.8, 70.1 ppm. HRMS (ESI): calcd. 
for C12H9O2NI [M+H]+ 325.9678; found 325.9593. 
 
General procedure for iodo-cyclization: In a round bottom flask containing the compound 7 (1 equiv., 
3 mmol) and 10 mL of THF were added 0.95 g of sodium carbonate (3 equiv., 9 mmol), 1.14 g of iodine 
(1.5 equiv., 4.5 mmol) and 0.51 g of silver nitrate (1 equiv., 3 mmol). The mixture was stirred overnight 
at room temperature. The medium was hydrolyzed by saturated solution of Na2S2O3 (10 mL) then 
extracted by dichloromethane (4 × 15 mL). The organic phase was washed with NaCl (3 × 10 mL), dried 
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with MgSO4 and evaporated under vacuum. Compound were isolated by column chromatography on 
silica gel using 5/95: ethyl acetate/petroleum ether as eluent. 
 
(E)-10-Iodo-3-(iodomethylene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 10a: Yellow-brown 
solid (1.16 g, 86 %); m.p. 184-186 °C; Rf = 0.32 (EtOAc/hexane, 20:80). 1H NMR (300 MHz, CDCl3): δ = 
7.63 (d, J = 8.2 Hz, 1 H), 7.53 (t, J = 8.1 Hz, 1 H), 7.42 (d, J = 8.3 Hz, 1 H), 7.34 (t, J = 8.1 Hz, 1 H), 6.37 (t, 
J = 1 Hz, 1 H), 5.13 (d, J = 1 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 153.8, 146.6, 136.7, 131.2, 
128.1, 124.2, 122.9, 120.2, 110.5, 69.5, 64.0, 43.6 ppm. IR (ATR): νmax = 3078, 2922, 1739, 1635, 1513 
cm-1. HRMS (ESI): calcd. for C12H7O2NI2 [M+H]+ 451.8638; found 451.8635.  
 
(E)-10-Iodo-7-(iodomethylene)-6,7-dihydro-9H-[1,3]dioxolo[4,5-f][1,4]oxazino[4,3-a]indol-9-one 
10b: White solid (0.60 g, 41 %); m.p. 213 °C; Rf = 0.40 (EtOAc/hexane, 20:80). 1H NMR (300 MHz, DMSO-
d6): δ = 7.78 (d, J = 0.5 Hz, 1 H), 7.32 (d, J = 0.5 Hz, 1 H), 6.93 (t, J = 1 Hz, 1 H), 6.57 (s, 2 H), 5.26 (d, J = 
3 Hz, 2 H) ppm.13C NMR (75 MHz, DMSO-d6): δ = 153.3, 149.4, 146.8, 145.5, 132.8, 125.3, 118.8, 101.7, 
99.6, 91.4, 69.0, 64.8, 43.6 ppm. IR (ATR): νmax = 3083, 2911, 1735, 1640, 1519, 1499 cm-1. HRMS (ESI): 
calcd. for C13H8O4NI2 [M+H]+ 495.8537; found 495.8534. 
 
6,7-Diiodo-5-(prop-2-yn-1-yl)-5H-[1,3]dioxolo[4,5-f]indole 10b’: beige solid (0.34 g, 25 %); m.p. 198 
°C. 1H NMR (300 MHz, CDCl3): δ = 6.89 (s, 1 H), 6.83 (s, 1 H), 5.98 (s, 2 H), 4.95 (d, J = 2.5 Hz, 2 H) 2.34 
(t, J = 2.5 Hz, 1H) ppm.13C NMR (75 MHz, DMSO-d6): δ = 145.4, 143.7, 132.3, 125.5, 110.9, 99.1, 94.0, 
92.1, 78.7, 75.4, 73.3, 38.6 ppm. HRMS (ESI): calcd. for C12H7O2NI2 [M]+ 450.8566; found 450.8554. 
 
(E)-10-Iodo-3-(iodomethylene)-8-methoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 10c: Pale 
brown solid (1.32 g, 92 %); m.p. 214-216 °C; Rf = 0.62 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 
7.32 (d, J = 9 Hz, 1 H), 7.17 (dd, J = 9 Hz, 2.4 Hz, 1 H), 6.93 (d, J = 3 Hz, 1 H), 6.35 (t, J = 1 Hz, 1 H), 5.09 
(d, J = 1 Hz, 2 H), 3.92 (s, 3 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 155.7, 153.6, 146.8, 131.8, 130.8, 
120.4, 119.2, 113.1, 102.1, 67.8, 64.9, 55.4, 43.5 ppm. IR (ATR): νmax = 3066, 1728, 1511, 1319, 1080, 
814 cm-1. HRMS (ESI): calcd. for C19H9I2NO3 [M+H]+ 481.8744; found 481.8746. 
 
(E)-8-Fluoro-10-iodo-3-(iodomethylene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 10d: Yellow 
solid (1.12 g, 80 %); m.p. 185-187 °C; Rf = 0.5 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.41 (m, 
1 H), 7.27-7.33 (m, 2 H), 6.39 (t, J = 1.2 Hz, 1 H), 5.11 (d, J = 1.5 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): 
δ = 159.4 (d, JC-F = 240 Hz), 153.7, 146.3, 133.4, 131.8 (d, JC-F = 9 Hz), 121.6, 117.7 (d, JC-F = 27 Hz), 111.9 
(d, JC-F = 8 Hz), 108.7 (d, JC-F = 23 Hz), 68.4 (d, JC-F = 7 Hz), 64.4, 43.8 ppm. 19F NMR (188 MHz, CDCl3) δ = 
-119.25 (td, J = 8.6 Hz, J = 4.2 Hz) ppm. IR (ATR): νmax = 3067, 1735, 1510, 1152, 1066, 853 cm-1. HRMS 
(ESI): calcd. for C12H6FI2NO2 [M+H]+ 469.8544; found 469.8544. 
 
(Z)-7-Iodo-10-(iodomethylene)-3-methoxy-10,11-dihydro-8H-benzo[g][1,4]oxazino[4,3-a]indol-8-
one 10e: 
solid (0.33 g, 21 %); m.p 219-221 °C. (EtOAc/EP, 20:80). 1H NMR (300 MHz, DMSO-d6): δ = 8.38 (d, J = 
9.1 Hz, 1 H), 7.67 (d, J = 9.1 Hz, 1 H), 7.58 (d, J = 2.5 Hz, 1 H), 7.50 (d, J = 9.1 Hz, 1 H), 7.39 (dd, J = 9.1 
Hz, 2.5 Hz, 1 H), 6.66 (s, 1 H), 5.76 (m, 2 H), 3.93 (s, 3 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 157.6, 
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153.7, 146.3, 135.5, 132.2, 126.6, 123.7, 123.3, 121.7, 118.30, 117.5, 116.3, 109.8, 66.0, 55.4, 54.9, 
47.3 ppm. HRMS (ESI): calcd. for C17H11I2NO3 [M+H]+ 531.8907; found 531.8920. 
 
2,3-Diiodo-7-methoxy-1-(prop-2-yn-1-yl)-1H-benzo[g]indole 10e‘:  
White solid (0.9 g, 61 %); m.p. 209-211 °C; Rf = 0.65 (EtOAc/EP, 20:80). 1H NMR (300 MHz, CDCl3): δ = 
8.41 (d, J = 9.1 Hz, 1 H), 7.48 (s, 2 H), 7.32-7.27 (m, 2 H), 5.45 (d, J = 2.5 Hz, 1 H), 3.96 (s, 3 H), 2.47 (t, J 
= 2.5 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 156.6, 133.4, 132.7, 128.0, 122.7, 122.5, 121.9, 117.6, 
116.9, 108.7, 92.5, 77.8, 75.9, 74.8, 55.5, 43.4 ppm. IR (ATR): νmax = 3237, 2115, 1383, 1231, 1036, 852 
cm-1. HRMS (ESI): calcd. for C16H11I2NO [M]+ 486.8930; found 486.8948 . 
 
(E)-9-Bromo-10-iodo-3-(iodomethylene)-3,4-dihydro-1H-pyrido[3',4':4,5]pyrrolo[2,1-c][1,4]oxazin-
1-one 10f: Yellow solid (0.82 g, 52 %); m.p. 255-257 °C; Rf = 0.12 (EtOAc/EP, 20:80). 1H NMR (300 MHz, 
CDCl3): δ = 8.28 (d, J = 5.8 Hz, 1 H), 7.41 (d, J = 5.8 Hz, 1 H), 6.45 (t, J = 1.1 Hz, 1 H), 5.12 (d, J = 1.1 Hz, 
2H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 153.3, 145.7, 143.0, 140.6, 136.3, 123.5, 123.2, 107.7, 67.6, 
65.6, 43.9 ppm. IR (ATR): νmax = 1737, 1220, 1097, 985, 736 cm-1. HRMS (ESI): calcd. for for 
C11H6BrI2N2O2 [M+H]+ 531.7730, found 531.7726. 
 
(E)-10-Iodo-3-(1-iodoethylidene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 10g: Yellow solid 
(1.10 g, 79 %); m.p. 194-196 °C; Rf = 0.66 (EtOAc/EP, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.61 (d, J = 
8.5 Hz, 1 H), 7.50 (t, J = 7.5 Hz, 1 H), 7.39 (d, J = 8 Hz, 1 H), 7.31 (t, J = 7.5 Hz, 1 H), 5.17 (q, J = 1.2 Hz, 2 
H), 2.65 (t, J = 1.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 154.3, 140.5, 136.6, 131.2, 127.9, 124.1, 
122.8, 120.6, 110.5, 83.8, 68.9, 46.1, 25.5 ppm. IR (ATR): νmax = 2507, 1665, 1266, 738 cm-1. HRMS (ESI): 
calcd. for C13H10I2NO2 [M+H]+ 465.8795; found 465.8799. 
 
(E)-10-iodo-3-(iodo(phenyl)methylene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 10h: Yellow 
solid (1.37 g, 87 %); m.p. 195-197 °C; Rf = 0.62 (EtOAc/EP, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.64 ( 
d, J = 8.2 Hz, 1 H), 7.58-7.52 (m, 1 H), 7.49-7.44 (m, 3 H), 7.40-7.27 (m, 3 H), 5.38 (s, 2 H) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 153.8, 140.6, 137.9, 136.7, 131.2, 129.9, 129.0, 128.4, 128.0, 124.2, 122.9, 120.3, 
110.5, 86.2, 69.2, 47.0 ppm. IR (ATR): νmax = 1737, 1220, 1097, 985, 736 cm-1. HRMS (ESI): calcd. for 
C18H12I2NO2 [M+H]+ 527.8951, found 527.8956. 
 
General procedure for Stille Cross-coupling: 
Monocoupling: In a schlenk tube, dried by a flame and under argon, compound 10 (1 equiv., 0.62 
mmol) was introduced with 9 mg of PdCl2(CH3CN)2 (5% mol) in 10 mL of DMF and the mixture was 
stirred for 15 min at room temperature before the addition of 0.24 g of organostannane (1.2 equiv., 
0.74 mmol). The mixture was stirred at room temperature overnight, and 20 mL of ethylacetate and 
10 mL of KF (1M) were added and the mixture was stirred for 1 h at room temperature. The precipitate 
obtained was filtered through a celite pad, washed by diethyl ether and water then the filtrate was 
extracted by diethyl ether (3 × 20mL). The organic phase was washed by NaCl (2 × 10 mL), dried by 
MgSO4 and concentrated under vacuum. Compound were isolated by column chromatography on silica 
gel using 2/98: ethyl acetate/petroleum ether as eluent. 
Bis coupling: In a schlenk tube, dried by a flame and under argon, compound 10 (1 equiv., 0.66 mmol) 
was introduced with 9.7 mg of PdCl2(CH3CN)2 (5% mol) in 10 mL of DMF and the mixture was stirred 
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for 15 min at room temperature before the addition of 0.63 g of organostannane (3 equiv., 1.98 mmol). 
The mixture was stirred at room temperature overnight. 20 mL of ethylacetate and 10 mL of KF (1M) 
were added and the stirring was continued for an additional 1 h at room temperature, then the 
precipitate obtained was filtered through a celite pad, washed by diethyl ether and water. The filtrate 
was extracted by diethyl ether (3 × 20 mL) and the organic phase was washed with NaCl (2 × 10 mL), 
dried by MgSO4 and concentrated under vacuum. Compound were isolated by column 
chromatography[34] on silica gel using 2/98: ethyl acetate/petroleum ether as eluent. 
 
(E)-3-Allylidene-10-iodo-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11a: Yellow solid (0.13 g, 61 
%); m.p. 154-156 °C; Rf = 0.37 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.63 (d, J = 8.2 Hz, 1 
H), 7.51 (t, J = 8.5 Hz, 1 H), 7.38 (d, J = 8.4 Hz, 1 H), 7.32 (t, J = 8 Hz, 1 H), 6.45 (ddd, J = 10.2 Hz, J = 11.5 
Hz, J = 16.5 Hz, 1 H), 6.22 (d, J = 11.5 Hz, 1 H), 5.42 (d, J = 16.5 Hz, 1 H), 5.32 (d, J = 10.2 Hz, 1 H), 5.09 
(s, 2 H) ppm.13C NMR (75 MHz, CDCl3): δ = 155.3, 142.4, 136.5, 131.2, 128.2, 127.8, 124.2, 122.7, 121.6, 
121, 115.6, 110.4, 68.7, 39.5 ppm. IR (ATR): νmax = 1720, 1513, 984, 896, 735 cm-1. HRMS (ESI, positive 
mode): calcd. for C14H11O2NI [M+H]+ 351.9829; found 351.9825. 
 
(E)-10-Iodo-3-((E)-3-(trimethylsilyl)allylidene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11b: 
Yellow solid (99 mg, 38 %); m.p. 163-165 °C; Rf = 0.63 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ 
= 7.62 (d, J = 9 Hz, 1 H), 7.51 (t, J = 9 Hz, 1 H), 7.42 (d, J = 9 Hz, 1 H), 7.31 (t, J = 7.5 Hz, 1 H), 6.56 (dd, J 
= 10.5 Hz, J = 18 Hz, 1 H), 6.21 (d, J = 10.5 Hz, 1 H), 6.11 (d, J = 18 Hz, 1 H), 5.10 (d, J = 0.75 Hz, 2 H), 
0.14 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 155.4, 142.0, 139.6, 136.6, 134.3, 131.3, 127.7, 124.3, 
122.8, 121.8, 118.0, 110.4, 68.7, 39.7, -1.2 ppm. IR (ATR): νmax = 2953, 2895, 1749, 1661, 1615, 1518 
cm-1. HRMS (ESI, positive mode): calcd. for C17H19O2NISi [M+H]+ 424.0224; found 424.0219. 
 
(E)-3-Allylidene-8-fluoro-10-iodo-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11c: Pale yellow 
solid (0.16 g, 71 %); m.p. 163-165 °C; Rf = 0.45 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.38-
7.23 (m, 3 H), 6.44 (ddd, J = 10.5 Hz, J = 11.2 Hz, J = 16.7 Hz, 1 H), 6.21 (d, J = 11.2 Hz, 1 H), 5.42 (d, J = 
16.7 Hz, 1 H), 5.33 (d, J = 10.7 Hz, 1 H), 5.07 (s, 2 H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 159.3 (J = 239 
Hz), 155.0, 142.1, 133.2, 131.8 (J = 10.4 Hz), 128.2, 128.0, 121.3, 117.3 (J = 27 Hz), 116.0, 111.7 (J = 10 
Hz), 108.8 (J = 25 Hz), 67.6 (J = 5 Hz), 39.8 ppm. 19F NMR (188 MHz, CDCl3): δ = -119.67 (td, J = 9 Hz, J = 
5 Hz) ppm. IR (ATR): νmax = 2970, 1724, 1515, 1224, 1159 cm-1. HRMS (ESI, positive mode): calcd. for 
C14H10FINO2 [M+H]+ 369.9734; found 369.9736. 
 
(E)-7-Allylidene-10-iodo-6,7-dihydro-9H-[1,3]dioxolo[4,5-f][1,4]oxazino[4,3-a]indol-9-one 11d: 
Yellow solid (0.20 g, 83 %); m.p. 167-169 °C; Rf = 0.13 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ 
= 6.94 (s, 1 H), 6.75 (s, 1 H), 6.42 (ddd, J = 21 Hz, 18 Hz, 12 Hz, 1 H), 6.19 (d, J = 12 Hz, 1 H), 6.05 (s, 2 
H), 5.41 (d, J = 18 Hz, 1 H), 5.31 (d, 1H, J = 12 Hz), 4.97 (s, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 154.9, 
150.2, 146.1, 142.4, 132.8, 128.2, 126.4, 120.8, 115.5, 101.9, 101.4, 89.8, 68.5, 39.8 ppm. IR (ATR): νmax 
= 2892, 1720, 1315, 1162, 1070, 900, 839 cm-1. HRMS (ESI, positive mode): calcd. for C15H11INO4 [M+H]+ 
395.9727; found 395.9726. 
 
(E)-10-Iodo-8-methoxy-3-((E)-3-(trimethylsilyl)allylidene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-
1-one 11e: Yellow oil (134 mg, 48%); Rf = 0.72 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.17 
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(d, J = 8.9 Hz, 1 H), 6.97 (dd, J = 8.9 Hz, J = 2.3 Hz, 1 H), 6.72 (d, J = 2.3 Hz), 6.42 (dd, J = 10.8 Hz, J = 18.1 
Hz, 1 H), 6.03 (d, J = 11 Hz, 1 H), 5.95 (d, J = 18.1 Hz, 1 H), 4.92 (s, 2H), 3.73 (s, 3 H), 0.00 (s, 9 H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 156.2, 155.2, 142.0, 139.3, 134.3, 131.8, 131.6, 121.5, 119.9, 117.6, 111.5, 
103.1, 67.3, 55.8, 39.7, -1.2 ppm. HRMS (ESI, positive mode): calcd. for C18H21INO3Si [M+H]+ 454.0335; 
found 454.0344.  
 
(E)-3-(But-3-en-2-ylidene)-10-iodo-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11f: Yellow solid 
(0.17 g, 74%); m.p. 235-237 °C; Rf = 0.56 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.62 (d, J = 
9 Hz, 1 H), 7.52-7.25 (m, 3 H), 6.63 (dd, J = 10.9 Hz, J = 17 Hz, 1 H), 5.46 (d, J = 17 Hz, 1 H), 5.34 (d, J = 
11 Hz, 1 H), 5.13 (s, 2 H), 2.02 (s, 3 H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 155.6, 139.1, 136.5, 131.4, 
131.2, 127.6, 124.2, 122.6, 120.3, 117.4, 110.5, 110.3, 68.1, 39.7, 11.1. IR (ATR): νmax = 2922, 1736, 
1094, 730 cm-1. HRMS (ESI, positive mode): calcd. for C15H13INO2 [M+H]+ 365.9985; found 365.9980. 
 
(Z)-10-Iodo-3-(1-phenylallylidene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11g: Yellow solid 
(0.11 g, 40%); m.p. 175-177 °C; Rf = 0.62 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.64 (d, J = 
6 Hz, 1 H), 7.55-7.35 (m, 5 H), 7.24 (d, J = 9 Hz, 2 H), 6.74 (dd, J = 9 Hz, J = 16.5 Hz, 1 H), 5.42 (d, J = 9 
Hz, 1 H), 5.25 (s, 2 H), 5.10 (d, J = 18 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 154.9, 138.5, 136.5, 
133.7, 131.8, 131.2, 130.0, 128.4, 128.0, 127.7, 126.4, 124.2, 122.7, 121.9, 121.3, 110.4, 68.3, 40.2 
ppm. IR (ATR): νmax = 1733, 1227, 737, 696. HRMS (ESI, positive mode): calcd. for C20H15INO2 [M+H]+ 
428.0142; found 428.0141. 
 
(E)-3-Allylidene-10-vinyl-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 12a: Yellow solid (49 mg, 30 
%); m.p. 127-129 °C; Rf = 0.37 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 8.08 (d, J = 8.2 Hz, 1 
H), 7.62 (dd, J = 11.7 Hz, J = 18.2 Hz, 1 H), 7.49 (t, J = 7.5 Hz, 1 H), 7.40 (d, J = 9 Hz, 1 H), 7.30 (t, J = 6 Hz, 
1 H), 6.48 (ddd, J = 10.3 Hz, J = 11.4 Hz, J = 16.5 Hz, 1 H), 6.19 (d, J = 11.3 Hz, 1 H), 6.07 (dd, J = 18.1 Hz, 
J = 1.5 Hz, 1 H), 5.58 (dd, J = 11.6 Hz, J = 1.5 Hz, 1 H), 5.41 (d, J = 18 Hz, 1 H), 5.31 (d, J = 10.5 Hz, 1 H), 
5.02 (s, 2 H), ppm. 13C NMR (75 MHz, CDCl3): δ = 156.2, 143.0, 136.4, 128.8, 128.4, 126.9, 125.4, 124.0, 
123.2, 122.4, 120.6, 118.3, 118.2, 115.1, 110.1, 38.8 ppm. IR (ATR): νmax = 3060, 1714, 1523, 889, 734 
cm-1. HRMS (ESI, positive mode): calcd. for C16H14NO2 [M+H]+ 252.1019; found 252.1017. 
 
(E)-7-Allylidene-10-vinyl-6,7-dihydro-9H-[1,3]dioxolo[4,5-f][1,4]oxazino[4,3-a]indol-9-one 12b: 
Yellow solid (51 mg, 26%); m.p. 206 °C; Rf = 0.21 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.54 
(dd, J = 18 Hz, 12 Hz, 1 H), 7.36 (s, 1 H), 6.77 (s, 1 H), 6.50-6.37 (m, 1 H), 6.17 (d, J = 12 Hz, 1 H), 6.04 (s, 
2 H), 5.89 (d, J = 18 Hz, 1 H), 5.52 (d, J = 12 Hz, 1 H), 5.42-5.27 (m, 2 H), 4.90 (s, 2 H) ppm. 13C NMR (75 
MHz, CDCl3): δ = 155.6, 149.3, 145.6, 142.9, 132.8, 128.9, 128.4, 124.3, 120.4, 119.8, 117.5, 114.9, 
101.7, 100.4, 89.9, 39.0 ppm. HRMS (ESI, positive mode): calcd. for C17H14NO4 [M+H]+ 296.0923; found 
296.0926.  
General procedure for Sonogashira Cross-coupling: 
Monocoupling: In a schlenk tube dried by a flame and under argon, compound 10 (1 equiv., 0.66 mmol) 
and alkyne (1.5 equiv., 0.99 mmol) were introduced with 10 mL of DMF. The solution was cooled to 0 
°C before the addition of 0.2 mL of Et3N (2.2 equiv., 1.46 mmol) and the solution was stirred for 15 min 
at 0 °C. Then 12.7 mg of CuI (0.066 mmol, 10% mol), 17.3 mg of PPh3 (0.066 mmol, 10% mol) and 7.4 
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mg of Pd(OAc)2 (0.033 mmol, 5% mol) were added and the mixture was stirred at room temperature 
overnight. 
30 mL of diethyl ether were added and the reaction medium was stirred for 5 min at room 
temperature, then 10 mL of NH4Cl were added and the mixture was stirred for 5 min. The precipitate 
formed was filtered on celite and washed by diehyl ether and water, and the filtrate was extracted by 
diethyl ether (3 × 20 mL). The organic phase was washed by saturated solution of NH4Cl (2 × 5 mL) and 
saturated solution of NaCl (2 × 10 mL), dried by MgSO4 and evaporated under vacuum. Compound 
were isolated by column chromatography on silica gel using 5/95: ethyl acetate/petroleum ether as 
eluent. 
Biscoupling: In a schlenk tube dried by a flame and under argon, 0.4 g of compound 10 (1 equiv., 0.88 
mmol) were introduced with 0.3 mL of 1-hexyne (3 equiv., 2.64 mmol) in 10 mL of DMF. The mixture 
was cooled to 0 °C and 0.54 mL of Et3N (4.4 equiv., 3.9 mmol) were added and the stirring was 
continued for 15 min at 0 °C before the addition of 17 mg of CuI (10% mol), 23 mg of PPh3 (10 % mol) 
and 9.9 mg of Pd(OAc)2 (10 % mol). The mixture was stirred at room temperature overnight. 30 mL of 
Et2O were added and the mixture was stirred for 5 min followed by the addition of 10 mL of NH4Cl and 
the stirring was continued for 5 min. 
The precipitate was filtered on celite, washed with ether and water and the filtrate was extracted by 
diethyl ether (3 × 20 mL). The organic phase was washed by NH4Cl (2 × 5 mL) and NaCl (5 × 10 mL), 
dried by MgSO4 and evaporated under vacuum. Compound were isolated by column chromatography 
on silica gel using 5/95: ethyl acetate/petroleum ether as eluent. 
 
(E)-3-(Hept-2-yn-1-ylidene)-10-iodo-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11h: Yellow solid 
(0.19 g, 74 %); m.p. 122-124 °C; Rf = 0.54 (EtOAc/PE, 10:90). 1H NMR (300 MHz, CDCl3): δ = 7.63 (d, J = 
9 Hz, 1 H), 7.52 (t, J = 7.5 Hz, 1 H), 7.39 (d, J = 9 Hz, 1 H), 7.33 (t, J = 7.5 Hz, 1 H), 5.67 (s, 1 H), 5.16 (s, 2 
H), 2.43 (t, J = 7.5 Hz, 2 H), 1.64-1.43 (m, 4 H), 0.97 (t, J = 7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ 
= 154.5, 150.8, 136.8, 131.3, 127.9, 124.2, 122.8, 121.1, 110.5, 99.0, 96.5, 73.1, 69.2, 40.7, 30.8, 22.2, 
19.5, 13.7 ppm. IR (ATR): νmax = 1742, 1070, 735 cm-1. MS (EI) m/z = 406 (20), 405 (M+., 100), 269 (26), 
250 (31), 222 (13), 221 (11), 208 (17), 207 (13), 180 (13), 178 (13), 128 (68), 114 (27), 102 (11), 101 
(56), 77 (17), 75 (22), 51 (19), 39 (10). HRMS (ESI, positive mode): calcd. for C18H17INO2 [M+H] 406.0298; 
found 406.0296. 
 
(E)-7-(Hept-2-yn-1-ylidene)-10-iodo-6,7-dihydro-9H-[1,3]dioxolo[4,5-f][1,4]oxazino[4,3-a]indol-9-
one 11i: Yellow solid (0.25 g, 85 %); m.p. 164-166 °C; Rf = 0.84 (EtOAc/PE, 20:80). 1H NMR (300 MHz, 
CDCl3): δ = 6.94 (s, 1 H), 6.76 (s, 1 H), 6.06 (s, 1 H), 5.64 (m, 1 H), 5.04 (d, J = 1.2 Hz, 2 H), 1.61-1.46 (m, 
4 H), 2.40 (dt, J = 6, 3 Hz, 2 H), 0.97 (t, J = 6 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 154.1, 150.8, 
150.3, 146.1, 133.1, 126.4, 119.7, 102.0, 101.3, 98.9, 96.2, 89.9, 73.2, 68.9, 40.9, 30.8, 22.2, 19.6, 13.7 
ppm. IR (ATR): νmax = 2951, 1729, 1491, 1037, 945, 841, 736 cm-1. HRMS (ESI, positive mode): calcd. for 
C19H17INO4 [M+H]+ 450.0196; found 450.0196. 
 
(E)-3-(Hept-2-yn-1-ylidene)-10-iodo-8-methoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11j: 
Brown oil (0.14 g, 48 %); Rf = 0.61 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.27 (d, J = 9 Hz, 1 
H), 7.15 (d, J = 9 Hz, 1 H), 6.90 (s, 1 H), 5.64 (s, 1 H), 5.10 (s, 2 H), 3.90 (s, 3 H), 2.42 (t, J = 6 Hz, 2 H), 
1.61-1.46 (m, 4 H), 0.97 (t, J = 7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 156.4, 154.3, 150.8, 
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132.2, 132.1, 121.0, 120.3, 111.6, 103.2, 99.0, 96.2, 73.1, 67.9, 55.9, 40.8, 30.8, 22.2, 19.5, 13.7 ppm. 
IR (ATR): νmax = 2928, 1734, 1512, 1449, 1167 cm-1. MS (EI) m/z = 436 (21), 435 (M+., 100), 299 (28), 284 
(10), 280 (22), 238 (15), 158 (21), 144 (12), 116 (13), 115 (19), 101 (12), 77 (17). HRMS (ESI, positive 
mode):calcd. for C19H19INO3 [M+H] 436.0404; found 436.0404. 
 
(E)-10-Iodo-3-(4-methoxybut-2-yn-1-ylidene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11k: 
Yellow-orange solid (70 mg, 27 %); m.p. 149-151 °C; Rf = 0.31 (EtOAc/EP, 20:80). 1H NMR (300 MHz, 
CDCl3): δ = 7.63 (d, J = 9 Hz, 1 H), 7.53 (t, J = 7.5 Hz, 1 H), 7.41 (d, J = 9 Hz, 1 H), 7.33 (t, J = 9 Hz, 1 H), 
5.72 (t, J = 3 Hz, 1 H), 5.19 (s, 2 H), 4.32 (d, J = 3 Hz, 2 H), 3.45 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ 
= 153.8, 152.4, 136.6, 131.1, 127.9, 124.0, 122.8, 120.6, 110.5, 94.9, 93.3, 78.8, 69.5, 60.5, 58.0, 40.7 
ppm. IR (ATR): νmax = 3050, 2953, 1744, 1670, 1614, 1518 cm-1. HRMS (ESI, positive mode): calcd. for 
C16H12O3NI [M+H] 393.9934; found 393.9930. 
 
(E)-10-Iodo-3-(3-phenylprop-2-yn-1-ylidene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11l: 
Yellow solid (31 mg, 11 %); m.p. 127-129 °C; Rf = 0.77 (EtOAc/EP, 20:80). 1H NMR (300 MHz, CDCl3): δ 
= 7.76-7.27 (m, 9 H), 5.90 (s, 1H), 5.25 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 154.1, 151.6, 136.8, 
131.6, 131.3, 129.1, 128.7, 128.1, 124.3, 123.0, 122.6, 120.9, 110.6, 97.4, 95.9, 81.8, 69.6, 40.9 ppm. 
IR (ATR): νmax = 2922, 1736, 1512, 1090, 735 cm-1. HRMS (ESI, positive mode): calcd. for C20H13INO2 
[M+H]+ 425.9985; found 425.9985. 
 
(E)-3-(Hept-2-yn-1-ylidene)-10-(hex-1-yn-1-yl)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 12c: 
Yellow oil (0.11 g, 34 %); Rf = 0.72 (EtOAc/PE, 10:90).1H NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 6 Hz, 1 
H), 7.50-7.44 (m, 1 H), 7.37 (d, J = 6 Hz, 1 H), 7.20-7.25 (m, 1 H), 5.64-5.62 (m, 1 H), 5.08 (s, 2 H), 2.60 
(t, J = 6 Hz, 2 H), 2.42 (dt, J = 2.2 Hz, J = 7 Hz, 2 H), 1.74-1.42 (m, 8 H), 0.97 (t, J = 7 Hz, 3 H), 0.95 (t, J = 
7 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 154.0, 151.3, 135.8, 129.2, 127.4, 122.4, 122.2, 121.5, 
110.2, 108.5, 100.2, 98.7, 96.0, 73.2, 71.9, 40.2, 30.9, 30.7, 22.1 (2C), 19.9, 19.5, 13.8, 13.7 ppm. IR 
(ATR): νmax = 2958, 2933, 1700, 1559, 739, 668 cm-1. HRMS (ESI, positive mode): calcd. for C24H26NO2 
[M+H]+ 360.1958; found 360.1959. 
 
General procedure for Suzuki-Miyaura Cross-coupling: 
Monocoupling: In a schlenk tube dried by a flame, and under argon, 0.2 g of compound 10a (1 equiv., 
0.44 mmol) were introduced with 10 mL of toluene and 2 mL of water. Then 0.12 g of potassium 
vinyltrifluoroborane (1.2 equiv, 0.53 mmol), 0.43 g of Cs2CO3 (3 equiv., 1.33 mmol) and 36 mg of 
PdCl2dppf (0.1 equiv., 0.044 mmol) were added respectively. After 24 hours at 70 ºC, 10 mL of HCl (1M) 
were added and the precipitate was filtered on Büchner then the filtrate was extracted by ethylacetate 
(3 × 20mL) and the organic phase was washed by NaCl (3 × 10mL), dried by MgSO4 and concentrated 
under vacuum. Compound were isolated by column chromatography on silica gel using 2/98: ethyl 
acetate/petroleum ether as eluent. 
Biscoupling: In a schlenk tube dried by a flame, and under argon, 0.2 g of compound 10a (1 equiv., 
0.44 mmol) were introduced with 10 mL of toluene and 2 mL of water. Then 0.13 g of potassium 
vinyltrifluoroborane (2.2 equiv., 0.97 mmol), 0.43 g of Cs2CO3 (3 equiv., 1.33 mmol) and 36 mg of 
PdCl2dppf (0.1 equiv., 0.044 mmol) were added respectively. After 24 hours at 70 ºC, 0.05 g of 
vinyltrifluoroborane and 0.02 g of PdCl2dppf were added and the reaction was let for 3 days. 10 mL of 
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HCl (1M) were added and the precipitate was filtered on Büchner then the filtrate was extracted by 
ethylacetate (3 × 20 mL) and the organic phase was washed by NaCl (3 × 10 mL), dried by MgSO4 and 
concentrated under vacuum. Compound were isolated by column chromatography on silica gel using 
2/98: ethyl acetate/petroleum ether as eluent. 
 
(E)-3-(Benzofuran-2-ylmethylene)-10-iodo-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11m: 
Yellow solid (0.11 g, 57 %); m.p. 177-179 °C; Rf = 0.57 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ 
= 7.62-7.45 (m, 5 H), 7.37-7.23 (m, 3 H), 6.73 (s, 1 H), 6.49 (s, 1 H), 5.60 (s, 2 H) ppm. 13C NMR (75 MHz, 
CDCl3): δ = 155.1, 154.8, 150.0, 143.5, 136.7, 131.2, 128.2, 127.8, 125.3, 124.1, 123.6, 122.8, 121.3, 
121.2, 111.1, 110.5, 108.5, 104.4, 68.7, 41.0 ppm. IR (ATR): νmax = 2917, 2850, 1731, 1232, 1174, 1080, 
734 cm-1. HRMS (ESI, positive mode): calcd. for C20H13INO3 [M+H]+ 441.9934; found 441.9931. 
 
(E)-10-Iodo-3-(thiophen-2-ylmethylene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 11n: Yellow 
solid (37 mg, 21 %); m.p. 188-190 °C; Rf = 0.48 (EtOAc/PE, 20:80). 1H NMR (300 MHz, CDCl3): δ = 7.63 
(d, J = 6 Hz, 1 H), 7.50 (t, J = 7.5 Hz, 1 H), 7.41-7.38 (m, 2 H), 7.32 (t, J = 9 Hz, 1 H), 7.11 (dd, J = 3.4 Hz, J 
= 5 Hz, 1 H), 7.04 (d, J = 3.4 Hz, 1 H), 6.80 (t, J = 0.9 Hz, 1 H), 5.32 (d, J = 3 Hz, 2 H) ppm. 13C NMR (75 
MHz, CDCl3): δ = 155.0, 142.0, 136.6, 134.7, 131.2, 128.6, 128.0, 127.8, 126.6, 124.2, 122.8, 110.4, 
109.2, 68.7, 40.3 ppm. IR (ATR): νmax = 1731, 1086, 735 cm-1. HRMS (ESI, positive mode): calcd. for 
C16H11INO2S [M+H]+ 407.9549; found 407.9551.  
 
(E)-3-((3,5-Dimethylisoxazol-4-yl)methylene)-10-iodo-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-
one 11o: Yellow solid (18 mg, 12 %), m.p. 242-244 °C; Rf = 0.22 (EtOAc/PE, 20:80). 1H NMR (300 MHz, 
DMSO-d6): δ = 7.86 (d, J = 8 Hz, 1 H), 7.52-7.44 (m, 2 H), 7.29 (t, J = 7 Hz, 1 H), 6.27 (s, 1H), 5.09 (s, 2 H), 
2.35 (s, 3 H), 2.14 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3): δ = 165.9, 159.1, 154.8, 145.3, 136.4, 130.2, 
127.0, 122.8, 122.4, 121.6, 112.3, 108.0, 101.9, 68.9, 40.2, 11.6, 10.0 ppm. IR (ATR): νmax = 1747, 1308, 
1234, 1155, 1090, 745 cm-1. HRMS (ESI, positive mode): calcd. for C17H14IN2O3 (M+H) 421.0043, found 
421.0046. 
 
(E)-8-fluoro-10-iodo-3-(pent-2-yn-1-ylidene)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-one 13: To a 
solution of compound 10d (1 equiv., 0.5 mmol) and pent-2-ynoic acid (3 equiv., 1.5 mmol) in DMF (3 
mL), was added copper (I) iodide (0.025 mmol, 0.05 equiv.), palladium (II) acetate (0.1 equiv., 0.05 
mmol), triphenylphosphine (0.1 equiv., 0.05 mmol) and triethylamine (2 equiv., 1 mmol) under argon 
atmosphere. The mixture was heated at 50 °C for 2 hours by microwave irradiation. After cooling to 
room temperature, the reaction mixture was diluted with water (10 mL) and extracted with diethyl 
ether (3 x 10 mL). The combined organic phases were washed with brine (2 x 20 mL), dried over 
anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was 
purified by flash chromatography (90:10 PE/EtOAc) and afforded 0.14 g of compound 13 as yellow solid 
with 70% yield. m.p. 148 °C. 1H NMR (300 MHz, CDCl3): δ = 7.41-7.34 (m, 1 H), 7.33-7.27 (m, 2 H), 5.67 
(bs, 1 H), 5.13 (s, 2 H), 2.43 (qd, J = 2.3 Hz, J = 7.5 Hz, 2 H), 1.24 (t, J = 7.5 Hz, 3 H) ppm. 13C NMR (75 
MHz, CDCl3): δ = 159.4 (J = 241.2 Hz), 154.1, 150.4, 133.4, 131.8, 122.5, 117.4 (J = 24.63 Hz), 112.0 (J = 
9.45 Hz), 108.8 (J = 27.52 Hz), 100.5, 96.8, 72.3, 68.0, 40.9, 14.0, 13.6 ppm. 19F NMR (188 MHz, CDCl3) 
δ = -119.03 ppm. HRMS (ESI, positive mode): calcd. for C16H12IFNO2 (M+H) 395.9897, found 395.9910. 
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Ethyl 1-(but-3-ynyl)-3-iodo-1H-indole-2-carboxylate 14a: 0.72 g of compound 4a (1.2 equiv., 2.28 
mmol) were introduced in a round bottom flask with 0.13 mg of 3-butyn-1-ol (1 equiv., 1.9 mmol) and 
596 mg of PPh3 (1.2 equiv., 2.28 mmol) in 20 mL of THF, 450 µL of DIAD (1.2 equiv., 2.28 mmol) were 
added at 0 °C and the mixture was stirred at RT overnight. The solvent was evaporated under vacuum. 
Purification by flash chromatography (95:5 PE/EtOAc) afforded the compound 14a as yellow oil (244 
mg, 35%). Rf = 0.8 (EtOAc/PE, 5:95). 1H NMR (300 MHz, CDCl3) δ = 7.68 (d, J = 8.1 Hz, 1 H), 7.48 (d, J = 
8.4 Hz, 1 H), 7.35 (t, J = J = 7.3 Hz, 1 H), 7.16 (t, J = 7.5 Hz, 1 H), 4.75 (t, J = 7.3 Hz, 2 H), 4.38 (q, J = 7.1 
Hz, 2 H), 2.70 (dt, J = 7.3 Hz, J = 2.7 Hz, 2 H), 1.97 (t, J = 2.7 Hz, 1H), 1.43 (t, J = 7.1 Hz, 3 H) ppm. 13C 
NMR (75 MHz, CDCl3) δ = 162.1, 139.2, 127.5, 126.1, 125.2, 122.8, 120.9, 111.1, 110.6, 81.1, 70.6, 43.5, 
29.8, 20.5, 14.5 ppm. IR (ATR): νmax = 1703, 1436, 1185, 1119, 722, 541 cm-1. HRMS (ESI, positive mode): 
calcd for C15H15INO2 (M+H) 368.01420, found 368.02992. 
 
Ethyl 3-iodo-1-(pent-4-ynyl)-1H-indole-2-carboxylate 14b: In a two-necked round bottom flask, 1.1 
equiv. of NaH 60 % (3.48 mmol) were dissolved in 6 mL of DMF, and 1 equiv. of indole 4a (3.16 mmol) 
in 5 mL of DMF were added drop by drop using a bromine bulb at 0 °C under argon. The mixture was 
stirred for 2 h at RT. 1.1 equiv. of 5-chloropent-1-yne (3.48 mmol) were added to the mixture drop by 
drop at 0 °C under argon and the mixture was heated at 70 °C overnight. The mixture was hydrolyzed 
by 10 mL of NH4Cl, extracted by EtOAc (3 × 20 mL), and the organic phase was washed with NaCl (6 × 
10 mL), dried by MgSO4 and evaporated under vacuum. Compound 14b was obtained as yellow oil (91 
mg, 76%).  
Rf = 0.71 (20:80 EtOAc/PE). 1H NMR (300 MHz, CDCl3): δ = 7.60 (d, J = 8.0 Hz, 1 H), 7.47 (d, J = 8.4 Hz,1 
H), 7.41 (t, J = 8.4 Hz, 1 H), 7.25 (t, J = 8.0 Hz, 1 H), 4.67 (t, J = 7.2 Hz, 2 H), 4.49 (q, J = 7.2 Hz, 2 H), 2.26 
(dt, J = 7.2 Hz, J = 2.5 Hz, 2 H), 2.11 (t, J = 2.5 Hz, 1 H), 2.05 (quint, J = 7.2 Hz, 2 H), 1.53 (t, J = 7.1 Hz, 3 
H) ppm. 13C NMR (CDCl3, 75 MHz): δ= 161.2, 138.5, 130.3, 127.9, 126.2, 124.1, 121.6, 110.6, 83.3, 69.4, 
67.5, 61.3, 44.8, 29.3, 16.0, 14.4 ppm. IR (ATR): νmax = 2917, 2849, 1737, 1706, 1464, 1242 cm-1. HRMS 
(ESI, positive mode): calcd for C16H17INO2 (M+H) 382.02985, found 382.02983. 
 
1-(But-3-ynyl)-3-iodo-1H-indole-2-carboxylic acid 15a:  
General procedure of saponification with 60 mg of 14a: Brown solid (50 mg, 91%); Rf = 0.19 (20:80 
EtOAc/PE). 1H NMR (300 MHz, CDCl3): δ = 7.62 (d, J = 8.1 Hz, 1 H), 7.54-7.40 (m, 2H), 7.34-7.18 (m, 1 
H), 4.81 (t, J = 7.1 Hz, 2 H), 2.75 (td, J = 7.0, J = 2.4 Hz, 2 H), 2.01 (t, J = 2.5 Hz, 1 H) ppm. 13C NMR (75 
MHz, CDCl3) : δ = 166.2, 139.2, 130.7, 127.2, 126.7, 124.6, 122.2, 111.0, 80.7, 71.2, 71.1, 44.8, 20.6. IR 
(ATR): νmax = 2917, 1677, 1437, 1119, 720 cm-1. HRMS (ESI, positive mode): calcd for C13H11INO2 (M+H) 
339.98290, found 339.98275. 
 
3-Iodo-1-(pent-4-ynyl)-1H-indole-2-carboxylic acid 15b: General procedure of saponification with 
0.77 g of 14b: White solid (0.7 g, 98%); m.p. = 191-193 °C; Rf = 0.19 (20:80 EtOAc/PE). 1H NMR (300 
MHz, CDCl3): δ = 7.61 (d, J = 8.1 Hz, 1,H), 7.49 (d, J = 8.2 Hz, 1,H), 7.41-7.46 (m, 1,H), 7.23-7.28 (m, 1,H), 
4.74 (t,J = 7.2 Hz, 2,H), 2.25 (dt, J = 6.5 Hz, 2.6 Hz, 2,H), 2.02-2.11 (m, 3,H) ppm.13C NMR (75 MHz, 
CDCl3): δ = 165.7, 139.3, 130.6, 127.1, 126.7, 124.6, 122.0, 110.9, 83.3, 70.4, 69.6, 45.1, 29.5, 16.2 ppm. 
IR (ATR): νmax = 3282, 2919-2504, 2163, 1666, 1263, 740 cm-1. HRMS (ESI, positive mode): calcd for 
C14H13INO2 (M+H) 353.99855, found 353.99821.  
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(E)-11-Iodo-3-(iodomethylene)-4,5-dihydro-1H,3H-[1,4]oxazepino[4,3-a]indol-1-one 16a: General 
procedure of iodocyclization with 140 mg of 15a: Beige solid (79 mg, 41%); Rf = 0.4 (20:80 EtOAc/PE). 
m.p. = 192-194 °C. 1H NMR (300 MHz, CDCl3): δ = 7.59 (d, J = 8.3 Hz, 1H), 7.47 (t, J = 8.3 Hz, 1H), 7.34 
(d, J = 8.2 Hz, 1H), 7.27 (t, J = 8.2 Hz, 1H), 6.43 (t, J = 1.5 Hz, 1H), 4.50 (t, J = 6.6 Hz, 2H), 3.17 (td, J = 6.6 
Hz, 1.5 Hz, 2H) ppm. 13C NMR (75 MHz, CDCl3): δ = 158.4, 151.4, 137.1, 130.5, 127.4, 127.3, 124.1, 
122.2, 110.0, 77.4, 70.8, 40.8, 34.6 ppm. IR (ATR): νmax = 1717, 1350, 1061, 738 cm-1. HRMS (ESI, positive 
mode): calcd for C13H10I2NO2 (M+H) 465.87954, found 465.87909.  
 
(E)-12-Iodo-3-(iodomethylene)-3,4,5,6-tetrahydro-1H-[1,4]oxazocino[4,3-a]indol-1-one 17b:  
General procedure of iodocyclization with 0.88 g of 15b: Beige solid (33 mg, 28%); m.p. = 162-164 °C; 
Rf = 0.38 (20:80 EtOAc/PE). 1H NMR (300 MHz, CDCl3): δ = 7.51 (d, J = 8.1 Hz, 1 H), 7.41 (t, J = 8.5 Hz, 1 
H), 7.30-7.24 (m, 2 H), 5.73 (bs, 1 H), 4.41-4.34 (m, 2 H), 2.75 (t, J = 6.5 Hz, 2 H), 2.14-2.05 (m, 2 H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 159.4, 155.0, 137.3, 130.4, 129.5, 126.7, 123.6, 122.0, 110.0, 67.8, 67, 
45.2, 31.9, 25.9 ppm. IR (ATR): νmax = 3048, 1725, 1632, 1077, 1036, 731 cm-1. HRMS (ESI, positive 
mode): calcd for C14H12I2NO2 (M+H) 479.89519, found 479.89536. 
 
Ethyl 1-(prop-2-ynyl)-1H-pyrrole-2-carboxylate 19: General procedure of propargylation with 2.1 g of 
18: Colorless oil (1.92 g, 72%); Rf = 0.73 (20:80 EtOAc/PE). 1H NMR (300 MHz, CDCl3): δ = 7.11 (dd, J = 
2.5 Hz, J = 1.8 Hz, 1 H), 6.98 (dd, J = 3.9 Hz, J = 1.8 Hz, 1 H), 6.17 (dd, J = 3.9 Hz, J =2.5 Hz, 1 H), 5.17 (d, 
J = 2.5 Hz, 2 H), 4.28 (q, J = 7.1 Hz, 2 H), 2.43 (t, J = 2.5 Hz, 1 H), 1.35 (t, J = 7.1 Hz, 3 H) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 161.0, 127.8, 121.9, 118.3, 108.5, 78.3, 73.7, 59.9, 38.1, 14.3 ppm. IR (ATR, cm-1): 
νmax = 3087, 1734, 1535, 1191, 867. HRMS (ESI, positive mode): calcd for C10H12NO2 (M+H) 178.08626, 
found 178.08634. 
 
1-(Prop-2-ynyl)-1H-pyrrole-2-carboxylic acid 20: General procedure of saponification with 0.52 g of 
19: Pale yellow solid (0.39 g, 91%); Rf = 0.21 (20:80 EtOAc/PE); m.p. = 148-150 °C. 1H NMR (300 MHz, 
CDCl3): δ = 7.21 (t, J = 2.3 Hz, 1 H), 7.13 (dd, J = 4.0 Hz, J = 1.7 Hz, 1 H), 6.22 (dd, J = 4.0 Hz, J = 2.3 Hz, 1 
H), 5.17 (d, J = 2.5 Hz, 2 H), 2.45 (t, J = 2.5 Hz, 1 H) ppm. 13C NMR (75MHz, CDCl3): δ = 165.8, 129.3, 
121.1, 120.9, 109.2, 78.1, 74.2, 38.5 ppm. IR (ATR): νmax = 3255, 2992-2548, 1654, 1260, 734 ppm. 
HRMS (ESI, positive mode): calcd for C8H8NO2 (M+H) 150.05496, found 150.05500.  
 
(E)-3,4-Dihydro-3-(iodomethylene)pyrrolo[2,1-c][1,4]oxazin-1-one 21: General procedure of 
iodocyclization with 0.35 g of 20: Brown solid (0.19 g, 30%); Rf = 0.52 (20:80 EtOAc/PE); m.p.= 88-90 
°C. 1H NMR (300 MHz, CDCl3): δ = 7.14 (dd, J = 4.1 Hz, J = 1.5 Hz, 1 H), 6.96-6.95 (m, 1H), 6.39 (dd, J = 
4.1 Hz, 2.5 Hz, 1 H), 6.25 (t, J = 1.2 Hz, 1 H), 4.98 (d, J = 1.2 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 
153.7, 147.3, 125.7, 118.2, 116.6, 112.0, 62.9, 45.6 ppm. IR (ATR, cm-1): νmax = 1718, 1327, 1166, 735. 
HRMS (ESI, positive mode): calcd for C8H7INO2 (M+H) 275.95160, found 275.95138. 
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